Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 7769 participants.

Also called NCT02344290

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 7,769 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02344290
Other papers using this trial's data
  • An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency Virus The Journal of infectious diseases, 2020-07-09 DOI, PubMed 32645164, PMC7347080 Not in the PMC Open Access subset.
  • Associations of Muscle Density and Area With Coronary Artery Plaque and Physical Function Journal of acquired immune deficiency syndromes (1999), 2023-10-01 DOI, PubMed 37368931, PMC10527277 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Asymptomatic SARS-CoV-2 Infection Is Common Among ART-Treated People With HIV Journal of acquired immune deficiency syndromes (1999), 2022-08-01 DOI, PubMed 35413022, PMC9246928 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021-12-06 DOI, PubMed 34134131, PMC8664454 In the PMC Open Access subset under CC BY-NC-ND.
  • Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE) Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023-06-08 DOI, PubMed 36825498, PMC10474926 Not in the PMC Open Access subset.
  • Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum The Journal of infectious diseases, 2020-07-09 DOI, PubMed 32645160, PMC7347077 Not in the PMC Open Access subset.
  • Clonal Hematopoiesis and Major Adverse Cardiac Events in People With HIV: Insights From the REPRIEVE Trial Arteriosclerosis, thrombosis, and vascular biology, 2026-01 DOI, PubMed 41195533, PMC12765570 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Cytomegalovirus IgG is Associated With Physical Function But Not Muscle Density in People With HIV Journal of acquired immune deficiency syndromes (1999), 2024-04-15 DOI, PubMed 38180893, PMC10947880 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Diabetes Risk Factors in People With HIV Receiving Pitavastatin Versus Placebo for Cardiovascular Disease Prevention : A Randomized Trial Annals of internal medicine, 2024-11 DOI, PubMed 39374532, PMC11573625 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE Trial Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026-02-04 DOI, PubMed 40576558, PMC12481469 Not in the PMC Open Access subset.
  • Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022-09-30 DOI, PubMed 35165682, PMC9525090 Not in the PMC Open Access subset.
  • Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial AIDS (London, England), 2026-04-01 DOI, PubMed 41217428, PMC12955952 In the PMC Open Access subset under CC BY-NC-ND.
  • Hepatic steatosis and nonalcoholic fatty liver disease are common and associated with cardiometabolic risk in a primary prevention cohort of people with HIV AIDS (London, England), 2023-11-15 DOI, PubMed 37503623, PMC10615699 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial The Journal of infectious diseases, 2020-07-09 DOI, PubMed 32645158, PMC7347082 Not in the PMC Open Access subset.
  • Pericoronary Adipose Tissue Density, Inflammation, and Subclinical Coronary Artery Disease Among People With HIV in the REPRIEVE Cohort Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023-12-15 DOI, PubMed 37439633, PMC10724469 Not in the PMC Open Access subset.
  • Pitavastatin to Prevent Cardiovascular Disease in HIV Infection The New England journal of medicine, 2023-08-24 DOI, PubMed 37486775, PMC10564556 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Pitavastatin, Procollagen Pathways, and Plaque Stabilization in Patients With HIV: A Secondary Analysis of the REPRIEVE Randomized Clinical Trial JAMA cardiology, 2025-03-01 DOI, PubMed 39661372, PMC11771813 Not in the PMC Open Access subset.
  • Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) Journal of acquired immune deficiency syndromes (1999), 2022-03-01 DOI, PubMed 35147583, PMC8837824 In the PMC Open Access subset under a licence that is not Creative Commons.
  • Statin Effects on Pericoronary Adipose Tissue Density in People With HIV: Insights From the REPRIEVE Trial JACC. Cardiovascular imaging, 2026-04 DOI, PubMed 41324519, PMC12766717 In the PMC Open Access subset under CC BY-NC-ND.
  • Statin-dependent and -independent pathways are associated with major adverse cardiovascular events in people with HIV The Journal of clinical investigation, 2025-11-17 DOI, PubMed 40924496, PMC12618077 In the PMC Open Access subset under CC BY.
  • The importance of methods for site performance evaluation in REPRIEVE, a longitudinal, global, multicenter trial Contemporary clinical trials, 2023-01 DOI, PubMed 36462699, PMC9891172 In the PMC Open Access subset under CC BY-NC-ND.
  • Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026-02-09 DOI, PubMed 40888096, PMC12477884 In the PMC Open Access subset under a licence that is not Creative Commons.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Botswana, Brazil, Canada, Haiti, India, Peru, Puerto Rico, South Africa, Spain, Thailand, Uganda, Zimbabwe (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02344290. Randomized; quadruple masking; primary purpose prevention. Start 2015-03-26 (actual); primary completion 2023-08-21 (actual). Results posted on 2024-10-15.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults
Acronym
REPRIEVE
Condition
HIV
Condition
Cardiovascular Diseases
Intervention (Drug)
Pitavastatin
Intervention (Drug)
Placebo
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID) (class: US National Institutes of Health)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)
Collaborator
Kowa Pharmaceuticals America, Inc. (class: industry)
Collaborator
Gilead Sciences (class: industry)
Collaborator
Massachusetts General Hospital (class: other)
Collaborator
NEAT ID Foundation (class: other)

Record details

Record id
cardio:ct-nct02344290
Content hash
052e84277bd7673282331e6bd23478a556bab4886d9e0fdfba5e25fadd86b161